NeoStem To Present At Multiple October Conferences

NEW YORK, Sept. 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple upcoming conferences in October.

2013 RAPS (Regulatory Affairs Professional Society): The Regulatory Convergence
  • Date and Time: Tuesday, October 1, 3:00 PM EDT
  • Venue: John B. Hynes Veterans Memorial Convention Center, Boston, MA
  • Session: Regulatory Requirements for Cell Therapy Tools
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

U.S. Food and Drug Administration (FDA) Public Workshop: Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Products
  • Date and Time: Monday, October 7, 11:20 AM EDT
  • Venue: FDA White Oak Campus, Silver Spring, MD
  • Session: Professional Societies, Industry Organizations, and Standards Related Organizations
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

BIO Investor Forum San Francisco
  • Date and Time: Wednesday, October 9, 10:30 AM PDT
  • Venue: The Palace Hotel, San Francisco, CA
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem

Stem Cell Meeting on the Mesa
  • Venue: Estancia La Jolla Hotel & Spa, La Jolla, CA
  • Session #1 Date and Time: Tuesday, October 15, 8:45 AM PDT
  • Session#1: Regulatory Challenges & Strategies For Regen Med Companies
  • Speaker #1: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT
  • Session #2 Date and Time: Tuesday, October 15, 11:15 AM PDT
  • Session #2: Company Presentation, NeoStem
  • Speaker #2: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem
  • Session #3 Date and Time: Tuesday, October 15, 3:00 PM PDT
  • Session #3: Company Presentation, PCT
  • Speaker #3: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

IBC's 3 rd Annual Cell Therapy Bioprocessing
  • Venue: Bethesda Marriott, Bethesda, MD
  • Session #1 Date and Time: Monday, October 21, 8:45 AM EDT
  • Session #1: Challenges and Future Directions for Commercial Scale Patient-Specific Production
  • Speaker #1: Brian Hampson, Senior Director, Innovation and Engineering
  • Session #2 Date and Time: Monday, October 21, 1:25 PM EDT
  • Session #2: Process Development for Commercial Success
  • Speaker #2: Robert Shaw, Vice President, Commercial Development

New York Society of Security Analysts' 17th Annual Life Science Conference
  • Date and Time: Wednesday, October 30, 10:00 EDT
  • Venue: NYSSA Conference Facilities , New York, NY
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

A bout NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

If you liked this article you might like

Neostem (NBS) Stock Declines After Pricing Secondary Public Offering

3 Breakout Stocks Under $10 for Your Trading Radar

Insider Trading Alert - UGI, NBS And MACK Traded By Insiders

Neostem (NBS): Today's Weak On High Volume Stock

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data